Table 2.

Demographic, clinical, and histologic variables by APOL1 risk status (all subjects)

VariableZero or One APOL1 Risk AllelesTwo APOL1 Risk AllelesP Value
Number of subjects6727
Onset age (yr)13 (8, 23)17 (13, 27)0.03
Enrollment age (yr)14 (10, 28)17 (13, 27)0.07
Baseline eGFR (ml/min per 1.73 m2)130 (83, 195)94 (68, 109)0.003
Baseline serum albumin (g/dl)3.1 (2.3, 3.7)3.0 (2.1, 3.8)0.84
Baseline urine protein-to-creatinine ratio3.6 (2.2, 7.1)4.7 (2.8, 10.2)0.28
Baseline serum suPAR (ng/ml)4297 (3402, 5405)4020 (3104, 4510)0.18
Change in suPAR (ng/ml)−27 (−1062, +764)+103 (−532, +1541)0.33
FSGS histologic variant0.02
 Collapsing38
 Tip102
 Cellular20
 Perihilar72
 Not otherwise specified4515
Segmental glomerulosclerosis (%)20 (9, 31)25 (19, 34)0.02
Global glomerulosclerosis (%)0 (0, 12)7 (0, 17)0.43
Total glomerulosclerosis (%)25 (12, 50)44 (24, 62)0.02
Tubular atrophy/fibrosis (%)10 (5, 25)20 (5, 60)<0.01
Arteriosclerosis (score)0 (0, 1)0 (0, 1.2)0.13
CR (remissions coded as one or two)1110.17
CR or PR sustained at week 52 (remission coded as one, two, or three)2970.16
Reached end stage kidney disease during the follow-up period810<0.01
  • Data are presented as medians (25th, 75th percentiles). Note that the total glomerulosclerosis is not the sum of segmental glomerulosclerosis plus global glomerulosclerosis, because the values are medians.